The design aimed to activate both MHC-I CD8+ and MHC-II CD4 T-cell functions because the activation of CD4+ cells plays important roles in promoting the DC- meditated cross-presentation of neoantigens and TAAs on the tumor surface and further enhances the antitumor effect of CD8+ T cells (44, 45). The gene discussed is CD4; the disease is neoplasm.